scholarly journals Double blind, placebo-controlled study of long-term intermittent dobutamine infusion with concomitant oral amiodarone for end stage heart failure

2003 ◽  
Vol 41 (6) ◽  
pp. 162-163
Author(s):  
Eleftheria Tsagalou ◽  
Maria Anastasiou-Nana ◽  
George Alexopoulos ◽  
John Terrovitis ◽  
Konstantinos Chalkias ◽  
...  
1994 ◽  
Vol 9 (5) ◽  
pp. 249-253 ◽  
Author(s):  
Masatsugu Hori ◽  
Hideyuki Sato ◽  
Michiko Karita ◽  
Kazuhisa Kodama ◽  
Noritake Hoki ◽  
...  

Circulation ◽  
1995 ◽  
Vol 92 (6) ◽  
pp. 1499-1506 ◽  
Author(s):  
Henry Krum ◽  
Jonathan D. Sackner-Bernstein ◽  
Rochelle L. Goldsmith ◽  
Marrick L. Kukin ◽  
Brian Schwartz ◽  
...  

CHEST Journal ◽  
2004 ◽  
Vol 125 (4) ◽  
pp. 1198-1204 ◽  
Author(s):  
John N. Nanas ◽  
Eleftheria P. Tsagalou ◽  
John Kanakakis ◽  
Serafim N. Nanas ◽  
John V. Terrovitis ◽  
...  

Circulation ◽  
1996 ◽  
Vol 93 (12) ◽  
pp. 2135-2141 ◽  
Author(s):  
Thomas S. Rector ◽  
Alan J. Bank ◽  
Kathleen A. Mullen ◽  
Linda K. Tschumperlin ◽  
Ronald Sih ◽  
...  

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
M Stratinaki ◽  
E Bousoula ◽  
I Malakos ◽  
M Zymatoura ◽  
E Fountas ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. Background Intra-aortic balloon pump (IABP) can be used as circulatory support in order to stabilize haemodynamically compromised patients as either a bridge to therapy or to further mechanical support. Based on the current literature its use should be limited to up to two weeks and there are not enough data regarding its long term use’s efficacy and possible complications. Purpose To review the possible complications of the long-term use of IABP Methods We restrospectively analysed the data from 24 consecutive patients with end-stage heart failure (ESHF) who received long-term IABP support and recorded the complications during their hospitalization as well as their outcome. Results 24 patients (14 male and 10 female) were included. In 5 of them ESHF was attributed to ischemic cardiomyopathy and the in 19 to dilated cardiomyopathy. Their mean age was 45.6+/-14 years. The mean duration of IABP support was 70.2 days (minimum 30days maximum 192 days). The mean ejection fraction (EF) was 20%. Regarding the pharmacological therapy, 12/24 patients were on dobutamine, 4/24 on dobutamine and milrinone and 8/24 on dobutamine and noradrenaline. Regarding the clinical course of these patients, 7/24 underwent heart transplantation, 2/24 managed to wean from IABP, 5/24 received left lentrivular assist device (LVAD), 6/24 received biventricular assist veice (BiVAD) and 4/24 died. In terms of complications they were recorded as following : infection 7/24, bleeding 3/24, thrombosis 4/24, heparin-induced thrombocytopenia(HIT) 5/24, hematoma 4/24, ischemia 0/24 and rupture 1/24. Conclusions   Although not indicated by the current guidelines, long term IABP can be used as a relatively safe  circulatory support method.


Sign in / Sign up

Export Citation Format

Share Document